Using advanced imaging to improve targeted cancer therapies
Hyperspectral Single Photon Imaging of Targeted Alpha-Emitters
This study is exploring new ways to improve a special cancer treatment that uses targeted radiation, making it more effective at killing cancer cells while reducing the chance of resistance, and it's designed for patients with both large tumors and small spread-out cancer spots.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10831489 on NIH RePORTER |
What this research studies
This research focuses on enhancing targeted alpha-emitter therapy (TAT) for cancer treatment by developing advanced imaging techniques. It aims to understand how these therapies can effectively kill cancer cells while minimizing resistance. By combining TAT with external beam radiation therapy, the research seeks to optimize treatment for both large tumors and small, widespread metastases. The study will gather crucial dosimetry information to help select suitable patients and streamline clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancer, particularly those with small, disseminated metastases.
Not a fit: Patients with localized tumors that can be effectively treated with conventional therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments with fewer side effects.
How similar studies have performed: Previous research has shown promising results with targeted alpha-emitter therapies, indicating potential for significant advancements in cancer treatment.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Du, Yong — Johns Hopkins University
- Study coordinator: Du, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.